BFM
AVTX icon

Boothbay Fund Management’s Avalo Therapeutics AVTX Stock Holding History

Boothbay Fund Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,400
Closed -$663K – 2254
2026
Q1 		$663K Buy
+44,400
New +$694K 0.01% 1179

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Boothbay Fund Management's AVTX Position: Q2 2026 in Review

Boothbay Fund Management increased its Avalo Therapeutics (AVTX) stake by 117% in Q2 2026, buying an estimated $5.97M and bringing the position to 702,051 shares worth $13M. The position accounts for 0.17% of the portfolio, ranked #115.

Boothbay Fund Management first reported a position in AVTX in Q4 2017 and has held it in 23 quarters since. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Boothbay Fund Management held 702,051 shares of Avalo Therapeutics worth $13M as of Q2 2026.
  • Boothbay Fund Management bought 377,793 Avalo Therapeutics shares in Q2 2026, an estimated $5.97M.
  • Avalo Therapeutics made up 0.17% of Boothbay Fund Management's portfolio in Q2 2026, its #115 holding.
  • Boothbay Fund Management first reported a position in Avalo Therapeutics in Q4 2017 and has held it in 23 quarters since.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.